CORRESP Filing
Dermata Therapeutics, Inc.
Date: Jan. 27, 2026 · CIK: 0001853816 · Accession: 0001493152-26-003812
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292885
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance File No. 333-292885 Acceleration Request Requested Date: January 29, 2026 Requested Time: 5:00 p.m. , Eastern Time
Re: Dermata Therapeutics, Inc.
Dear Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the "Company") hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
DERMATA
THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm January 27, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-292885 Acceleration Request Requested Date: January 29, 2026 Requested Time: 5:00 p.m. , Eastern Time Dear Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the "Company") hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission. Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions. Sincerely, DERMATA THERAPEUTICS, INC. By: /s/ Gerald T. Proehl Name: Gerald T. Proehl Title: Chief Executive Officer THIS PAGE IS INTENTIONALLY LEFT BLANK IT IS NOT A PART OF EDGAR SUBMISSION